Pacira BioSciences (PCRX) Net Margin (2010 - 2026)

Pacira BioSciences' Net Margin history runs 17 years deep, the most recent figure standing at 1.64% for Q1 2026.

• On a quarterly basis, Net Margin fell 120.0% year-over-year to 1.64% in Q1 2026; TTM through Mar 2026 was 0.7%, a 1546.0% increase from a year earlier, with the FY2025 full-year figure at 0.97%, up 1517.0% from the prior year.
• Net Margin climbed to 1.64% in Q1 2026 per PCRX's latest filing, from 0.83% in the prior quarter.
• Across five years, Net Margin topped out at 15.2% in Q2 2023 and bottomed at 85.11% in Q3 2024.
• The 5-year median for Net Margin is 3.03% (2025), against an average of 0.81%.
• Across the five-year window, Net Margin sank 9173 bps in 2024 and jumped 8813 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 2.05% in 2022, then jumped by 569 bps to 13.72% in 2023, then plunged by 38 bps to 8.57% in 2024, then tumbled by 90 bps to 0.83% in 2025, then soared by 98 bps to 1.64% in 2026.
• Per Business Quant, the three latest PCRX Net Margin figures stand at 1.64% (Q1 2026), 0.83% (Q4 2025), and 3.03% (Q3 2025).